|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: DLX5 |
Gene summary for DLX5 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | DLX5 | Gene ID | 1749 |
| Gene name | distal-less homeobox 5 | |
| Gene Alias | SHFM1 | |
| Cytomap | 7q21.3 | |
| Gene Type | protein-coding | GO ID | GO:0000902 | UniProtAcc | P56178 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 1749 | DLX5 | LZE2T | Human | Esophagus | ESCC | 4.39e-03 | 4.57e-01 | 0.082 |
| 1749 | DLX5 | LZE4T | Human | Esophagus | ESCC | 8.51e-04 | 4.15e-01 | 0.0811 |
| 1749 | DLX5 | LZE7T | Human | Esophagus | ESCC | 6.10e-07 | 7.03e-01 | 0.0667 |
| 1749 | DLX5 | LZE21D1 | Human | Esophagus | HGIN | 3.51e-04 | 3.54e-01 | 0.0632 |
| 1749 | DLX5 | LZE22T | Human | Esophagus | ESCC | 1.16e-04 | 8.09e-01 | 0.068 |
| 1749 | DLX5 | LZE24T | Human | Esophagus | ESCC | 1.33e-04 | 2.51e-01 | 0.0596 |
| 1749 | DLX5 | LZE21T | Human | Esophagus | ESCC | 2.27e-07 | 5.95e-01 | 0.0655 |
| 1749 | DLX5 | P2T-E | Human | Esophagus | ESCC | 4.30e-10 | 1.78e-01 | 0.1177 |
| 1749 | DLX5 | P4T-E | Human | Esophagus | ESCC | 2.55e-28 | 7.60e-01 | 0.1323 |
| 1749 | DLX5 | P5T-E | Human | Esophagus | ESCC | 4.41e-07 | 2.04e-01 | 0.1327 |
| 1749 | DLX5 | P9T-E | Human | Esophagus | ESCC | 1.49e-27 | 8.34e-01 | 0.1131 |
| 1749 | DLX5 | P10T-E | Human | Esophagus | ESCC | 2.85e-73 | 1.45e+00 | 0.116 |
| 1749 | DLX5 | P11T-E | Human | Esophagus | ESCC | 6.76e-10 | 8.18e-01 | 0.1426 |
| 1749 | DLX5 | P12T-E | Human | Esophagus | ESCC | 1.77e-86 | 1.87e+00 | 0.1122 |
| 1749 | DLX5 | P15T-E | Human | Esophagus | ESCC | 5.54e-69 | 2.11e+00 | 0.1149 |
| 1749 | DLX5 | P16T-E | Human | Esophagus | ESCC | 1.85e-55 | 1.21e+00 | 0.1153 |
| 1749 | DLX5 | P20T-E | Human | Esophagus | ESCC | 5.96e-07 | 2.30e-01 | 0.1124 |
| 1749 | DLX5 | P22T-E | Human | Esophagus | ESCC | 1.13e-16 | 3.81e-01 | 0.1236 |
| 1749 | DLX5 | P23T-E | Human | Esophagus | ESCC | 2.38e-14 | 4.77e-01 | 0.108 |
| 1749 | DLX5 | P24T-E | Human | Esophagus | ESCC | 1.97e-10 | 3.27e-01 | 0.1287 |
| Page: 1 2 3 4 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:006156423 | Thyroid | ATC | axon development | 220/6293 | 467/18723 | 6.85e-10 | 1.80e-08 | 220 |
| GO:000740919 | Thyroid | ATC | axonogenesis | 197/6293 | 418/18723 | 5.09e-09 | 1.13e-07 | 197 |
| GO:0030177110 | Thyroid | ATC | positive regulation of Wnt signaling pathway | 80/6293 | 140/18723 | 8.75e-09 | 1.86e-07 | 80 |
| GO:000717823 | Thyroid | ATC | transmembrane receptor protein serine/threonine kinase signaling pathway | 170/6293 | 355/18723 | 1.40e-08 | 2.87e-07 | 170 |
| GO:0090263110 | Thyroid | ATC | positive regulation of canonical Wnt signaling pathway | 62/6293 | 106/18723 | 1.26e-07 | 2.09e-06 | 62 |
| GO:006034813 | Thyroid | ATC | bone development | 102/6293 | 205/18723 | 1.18e-06 | 1.52e-05 | 102 |
| GO:006054121 | Thyroid | ATC | respiratory system development | 100/6293 | 203/18723 | 2.66e-06 | 3.08e-05 | 100 |
| GO:006032511 | Thyroid | ATC | face morphogenesis | 21/6293 | 28/18723 | 8.94e-06 | 8.95e-05 | 21 |
| GO:001017111 | Thyroid | ATC | body morphogenesis | 28/6293 | 43/18723 | 2.35e-05 | 2.06e-04 | 28 |
| GO:006032411 | Thyroid | ATC | face development | 28/6293 | 44/18723 | 4.39e-05 | 3.54e-04 | 28 |
| GO:003090015 | Thyroid | ATC | forebrain development | 164/6293 | 379/18723 | 4.85e-05 | 3.87e-04 | 164 |
| GO:0060349 | Thyroid | ATC | bone morphogenesis | 50/6293 | 93/18723 | 4.87e-05 | 3.88e-04 | 50 |
| GO:006032311 | Thyroid | ATC | head morphogenesis | 22/6293 | 32/18723 | 5.14e-05 | 3.99e-04 | 22 |
| GO:002153712 | Thyroid | ATC | telencephalon development | 113/6293 | 248/18723 | 5.61e-05 | 4.32e-04 | 113 |
| GO:00487053 | Thyroid | ATC | skeletal system morphogenesis | 101/6293 | 220/18723 | 9.48e-05 | 6.93e-04 | 101 |
| GO:190152221 | Thyroid | ATC | positive regulation of transcription from RNA polymerase II promoter involved in cellular response to chemical stimulus | 16/6293 | 22/18723 | 2.03e-04 | 1.35e-03 | 16 |
| GO:00600211 | Thyroid | ATC | roof of mouth development | 42/6293 | 85/18723 | 1.83e-03 | 9.02e-03 | 42 |
| GO:00485688 | Thyroid | ATC | embryonic organ development | 172/6293 | 427/18723 | 2.08e-03 | 9.84e-03 | 172 |
| GO:00351074 | Thyroid | ATC | appendage morphogenesis | 63/6293 | 138/18723 | 2.13e-03 | 1.00e-02 | 63 |
| GO:00351084 | Thyroid | ATC | limb morphogenesis | 63/6293 | 138/18723 | 2.13e-03 | 1.00e-02 | 63 |
| Page: 1 2 3 4 5 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| DLX5 | MES | Cervix | HSIL_HPV | DSG1,AMTN,KLK8, etc. | 4.57e-01 |  |
| DLX5 | STM | Endometrium | Healthy | MSX1,HLA-B,SH3YL1, etc. | 2.36e-01 |  |
| DLX5 | CILIA | Endometrium | Healthy | MSX1,HLA-B,SH3YL1, etc. | 6.96e-02 | |
| DLX5 | PLA | Endometrium | ADJ | KRT18,MSX1,WFDC2, etc. | 4.80e-02 |  |
| DLX5 | TH1 | Endometrium | ADJ | KRT18,MSX1,WFDC2, etc. | 1.12e-02 | |
| DLX5 | M1MAC | Endometrium | AEH | KRT18,MSX1,WFDC2, etc. | 4.61e-02 |  |
| DLX5 | PLA | Endometrium | AEH | KRT18,MSX1,WFDC2, etc. | 3.07e-02 | |
| DLX5 | M1MAC | Endometrium | EEC | KRT18,MSX1,WFDC2, etc. | 6.86e-02 |  |
| DLX5 | PERI | Esophagus | ADJ | RGS5,ARHGAP15,KCNJ8, etc. | 1.39e-01 |  |
| DLX5 | PERI | Esophagus | ESCC | RGS5,ARHGAP15,KCNJ8, etc. | 4.37e-01 |  |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 2 3 4 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| DLX5 | SNV | Missense_Mutation | c.590N>C | p.Lys197Thr | p.K197T | P56178 | protein_coding | deleterious(0) | probably_damaging(0.987) | TCGA-BH-A18V-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
| DLX5 | SNV | Missense_Mutation | novel | c.499N>T | p.Arg167Cys | p.R167C | P56178 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-OL-A66I-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | CR |
| DLX5 | SNV | Missense_Mutation | rs773641315 | c.355G>A | p.Glu119Lys | p.E119K | P56178 | protein_coding | tolerated(0.34) | benign(0.341) | TCGA-PE-A5DE-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | taxotere | CR |
| DLX5 | SNV | Missense_Mutation | c.546N>C | p.Lys182Asn | p.K182N | P56178 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-AA-A010-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Chemotherapy | folinic | CR | |
| DLX5 | SNV | Missense_Mutation | c.500G>A | p.Arg167His | p.R167H | P56178 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-AD-6548-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| DLX5 | SNV | Missense_Mutation | novel | c.134C>A | p.Ser45Tyr | p.S45Y | P56178 | protein_coding | deleterious(0.02) | probably_damaging(0.964) | TCGA-CA-6717-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Chemotherapy | oxaliplatin | CR |
| DLX5 | SNV | Missense_Mutation | c.413G>A | p.Arg138His | p.R138H | P56178 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-D5-6930-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD | |
| DLX5 | SNV | Missense_Mutation | novel | c.68C>A | p.Thr23Lys | p.T23K | P56178 | protein_coding | tolerated(0.58) | benign(0.03) | TCGA-G4-6297-01 | Colorectum | colon adenocarcinoma | Female | <65 | III/IV | Chemotherapy | fluorouracil | PD |
| DLX5 | SNV | Missense_Mutation | c.500G>A | p.Arg167His | p.R167H | P56178 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-AG-A002-01 | Colorectum | rectum adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD | |
| DLX5 | SNV | Missense_Mutation | c.691N>T | p.Arg231Cys | p.R231C | P56178 | protein_coding | deleterious(0.01) | probably_damaging(0.924) | TCGA-AG-A015-01 | Colorectum | rectum adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | PD |
| Page: 1 2 3 4 5 6 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |